Addressing these limitations requires more rigorous research efforts, including multicenter clinical trials and comprehensive experiments, to better understand the molecular mechanisms driving JAK-STAT signaling in CRC and to evaluate the potential therapeutic benefits of targeting this pathway. The gene discussed is SOAT1; the disease is colorectal carcinoma.